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Patients with essential hypertension, a hereditary polygenic 
disease, are eventually complicated with stroke, cardiovascu-
lar remodeling, and nephrosclerosis. These complications are 
practical  targets  for  therapy  of  essential  hypertension  with 
antihypertensive medicines. Spontaneously hypertensive rats 
(SHR), a genetic animal model for essential hypertension, show 
exaggerated growth of cardiovascular organs in comparison 
with  normotensive  Wistar–Kyoto  (WKY)  rats.1,2  Enhanced 
DNA synthesis and organ hypertrophy have been described 
in SHR even as early as the day of birth.3–5 SHR-derived vas-
cular smooth muscle cells (VSMCs) in culture show a higher 
specific growth rate, abnormal contact inhibition, accelerated 
entry into S phase of the cell cycle, and nonspecific hyperpro-
liferation in response to various growth factors in comparison 
to cells from WKY rats.6,7 These behaviors may reflect intrin-
sic abnormalities in SHR that are not caused by pressure over-
load because there is no blood pressure in culture. Therefore, 
these characteristics of VSMCs from SHR appear to be associ-
ated with genetic abnormalities. We found that SHR-derived 
VSMCs  generate  angiotensin  II  (Ang  II)  in  homogenous 
  cultures.8 We have reported that the mechanism underlying 
this enhanced generation of Ang II in SHR-derived VSMCs 
appears to be a change from the contractile to the synthetic 
phenotype in comparison to cells from WKY rats.9,10
It is possible that genetic abnormalities are involved in the 
exaggerated growth and synthetic phenotype of VSMCs from 
SHR. We investigated the genes that are responsible and found 
by  microarray  analysis  that  the  messenger  RNA  (mRNA) 
encoding  complement  3  (C3)  is  expressed  only  in  VSMCs 
from SHR and is associated with both the synthetic phenotype 
and exaggerated growth.11 At the same time, we demonstrated 
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Background
Spontaneously hypertensive rats (Shr)-derived vascular smooth 
muscle cells (VSmcs) show exaggerated growth with a synthetic 
phenotype and angiotensin II (ang II)-production. To evaluate 
the contribution of complement 3 (c3) or c3a toward these 
abnormalities in Shr, we examined effects of a c3a receptor 
inhibitor on proliferation, phenotype, and ang II-production in 
VSmcs from Shr and Wistar–Kyoto (WKY) rats.
Methods
Expression of pre-pro-c3 messenger rNa (mrNa) and c3 protein was 
evaluated by reverse transcription-Pcr and western blot analyses, 
and c3a receptor mrNa was evaluated by reverse transcription-Pcr 
analysis in quiescent VSmcs from Shr and WKY rats. We examined 
the effects of the c3a inhibitor, SB290157, on proliferation and the 
expression of phenotype-marker and Krueppel-like factor 5 (KLF-5) 
mrNas in VSmcs from Shr and WKY rats. We examined effects of c3a 
receptor inhibitor, SB290157, on ang II-production in conditioned 
medium of VSmcs from Shr and WKY rats by a radioimmunoassay.
results
Expression of pre-pro-c3 mrNa and c3 protein was significantly 
higher in Shr VSmcs than WKY VSmcs. SB290157 significantly 
inhibited proliferation of VSmcs from Shr, but not in cells from WKY 
rats. relative to WKY VSmcs, SB290157 significantly increased the low 
expression of Sm22α mrNa and decreased the high expression of 
osteopontin mrNa in Shr VSmcs. SB290157 significantly decreased 
the high expression of KLF-5 and ang II-production in VSmcs from 
Shr, but not in cells from WKY rats.
conclusions
c3a induces exaggerated growth, a synthetic phenotype and ang 
II-production in Shr-derived VSmcs. c3a may be primarily involved 
in cardiovascular remodeling in hypertension.
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that C3 also changes renal mesangial cells to the synthetic 
phenotype.12  We  investigated  mechanisms  underlying  the 
C3-induced phenotypic changes and found that C3 stimulates 
Kruppel-like factor 5 (KLF-5) promoter activity through extra-
cellular signal-regulated kinase (ERK) signaling.13
C3 is a 190 kDa glycoprotein that consists of two   polypeptide 
chains,  which  are  produced  from  liver,  monocytes,  and 
  macrophages,  and  it  is  essential  for  eliciting  the  comple-
ment response.14 C3 from pre-pro-C3 mRNA is secreted after 
  cleavage  of  the  heterodimer,  and  then  C3  is  proteolytically 
cleaved into C3a (molecular weight 9,000) and C3b   (molecular 
weight 185,000). C3a is an anaphylotoxin, and C3b serves as an 
opsonizing agent.15 We have demonstrated that the increases in 
Ang II-production in VSMCs in homogeneous culture are asso-
ciated with changes to the synthetic phenotype in VSMCs.8,16
In the current study, in order to evaluate whether C3 or 
C3a is associated with the exaggerated growth of the synthetic 
  phenotype and increased Ang II-production in VSMCs from 
SHR, we examined effects of the C3a receptor inhibitor on 
proliferation, phenotype, and Ang II-production in VSMCs 
from SHR and WKY rats.
Methods
Ethics and animals. Our investigation conformed to the Guide 
for the Care and Use of Laboratory Animals published by the 
US National Institutes of Health (NIH Publication No. 85-23, 
1996). The ethics committee of the Nihon University School of 
Medicine examined every research protocol involving the use 
of living animals. SHR/Izm and WKY/Izm rats were obtained 
from Japan SLC (Hamamatsu, Japan).
Cell  culture  and  establishment  of  quiescence.  VSMCs  were 
obtained from aortic explants from 3-week-old prehypertensive 
male SHR/Izm and WKY/Izm rats. VSMCs were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM) with 10% calf 
serum (Gibco Life Technologies, Gaithersburg, MD), 100 U/ml 
penicillin, and 100 mg/ml streptomycin. Experiments were per-
formed on cells between the 5th and 10th passages. Trypsinized 
cells  were  plated  into  24-well  culture  dishes  at  a  density  of 
105 cells/cm2. They were allowed to grow in DMEM contain-
ing 10% calf serum for 24 h, and the culture medium was then 
changed to DMEM with 0.2% calf serum. The cells were incu-
bated in this medium for 48–72 h to establish quiescence.
Proliferation  of  VSMCs.  VSMCs  from  SHR  and  WKY  rats 
were inoculated and grown into DMEM containing 5% calf 
serum in the absence or presence of 0.1 µmol/l SB290157 in 
24-well culture dishes at a density of 105 cells/cm2. Cells were 
trypsinized with 0.05% trypsin at 24, 48, and 72 h after inocu-
lation, and cell numbers were counted in a Coulter counter 
(Coulter Electronics, Luton, UK).
Semiquantitative  reverse  transcription-PCR  analysis.  Total 
RNAs from samples were extracted from quiescent VSMCs 
from SHR and WKY rats with ISOGEN (Nippon Gene, Tokyo, 
Japan). Primer sequences are listed in Table 1. 18S   ribosomal 
RNA  was  used  as  an  internal  control.  To  confirm  that  no 
genomic  DNA  was  co-amplified  by  PCR,  control  reverse 
transcription-PCR  experiments  were  performed  with  each 
set of primers but without reverse transcriptase; no product 
was  amplified.  For  semiquantative  analysis  of  mRNA,  the 
kinetics of the PCR reaction were monitored; the number of 
cycles at which the PCR products were detectable on the gel 
was compared between samples.17 Serial tenfold dilutions of 
complementary DNA (100, 10, and 1 ng) were amplified; the 
PCR products were detectable at earlier cycles with increasing 
amounts of complementary DNA. PCR was performed for 30 
cycles in a DNA thermal cycler (Perkin-Elmer Cetus, Waltham, 
MA), and products were separated by electrophoresis on 1.5% 
agarose gels, stained with ethidium bromide, and visualized by 
ultraviolet illumination.
Western  blot  analysis  for  C3  protein  in  VSMCs.  VSMCs 
(5 × 104 cells/cm2) were disrupted with lysis buffer (50 mmol/l 
Tris-HCl  (pH  8.0),  150 mmol/l NaCl,  0.02%  sodium  azide, 
100 µg/ml  phenylmethylsulfonyl  fluoride,  1 µg/ml    aprotinin, 
1% Triton X-100). Total proteins were extracted and purified 
with 100 µl of chloroform and 400 µl of methanol. Protein sam-
ples were boiled for 3 min and subjected to electrophoresis on 
8% polyacrylamide gels and then transblotted to nitrocellulose 
membranes (Bio-Rad Laboratories, Hercules, CA). Blots were 
incubated with rabbit polyclonal   antibodies   specific for C3 (Santa 
Cruz Biotechnology, Santa Cruz, CA) or a mouse monoclonal 
antibody specific for α-tubulin (Sigma, St Louis, MO) as an 
internal control, and were then incubated with goat anti-  rabbit 
immunoglobulin G or goat anti-mouse   immunoglobulin  G 
(Bio-Rad Laboratories). Immunocomplexes were detected by 
enhanced   chemiluminescence (ECL, Amersham, UK).
Measurement of Ang II in conditioned medium. VSMCs (106) 
from SHR and WKY rats were inoculated in 10 cm2 wells with 
table 1 | Pcr primers and product sizes




Pre-pro-c3 5′ 5′-caGcaGaccTcaGTGaccaa-3′ 351
3′ 5′-aTaGcTGTcaGccaGGTGcT-3′
c3a receptor 5′ 5′-GaccTacacTcaGGGc-3′ 376
3′ 5′-aTGacGGacGGGaTaaG-3′
Sm22α 5′ 5′-TTGaaGGccaaTcacGTGcTT-3′ 312
3′ 5′-aaGccaGTGaaGGTGccTGaG -3′
Osteopontin 5′ 5′-TGGcTTacGGacTGaGGTca-3′ 486
3′ 5′-GaccTcaGaaGaTGaacTcT-3′
KLF-5 5′ 5′-accTacTTTcccccaTcacc-3′ 205
3′ 5′-ccGGGTTacTccTTcTGTTG-3′
18S rrNa 5′ 5′-cGacGacccaTTcGaacGTcT-3′ 312
3′ 5′-GcTaTTGGaGcTGGaaTTaccG-3′
KLF-5, Kruppel-like factor 5; mRNA, messenger RNA; pre-pro-C3, pre-pro-complement 3; 
rRNA, ribosomal RNA.286     march 2012 | VOLUmE 25 NUmBEr 3 | AMERICAN JOURNAL OF HYPERTENSION
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DMEM  containing  10%  calf  serum  and  incubated  for  24 h. 
The  cells  were  then  washed  twice  with  phosphate-buffered 
saline, and incubated first for 24 h with serum-free DMEM and 
then for 48 h with 2 ml of fresh serum-free DMEM in the absence 
or presence of 0.1 µmol/l SB290157. The culture medium was 
collected and centrifuged at 600g for 10 min, and the resulting 
supernatant (conditioned medium) was collected and treated 
with 1 mmol/l each of aprotinin, leupeptin, and pepstatin A 
as well as 0.1 mmol/l phenylmethylsulfonyl   fluoride. Samples 
were applied to a Sep-Pak C18 cartridge (Waters Associates, 
Milford, MA), and peptides were eluted with 3 ml of methanol-
water-trifluoroacetic acid (80:19.9:0.1, vol/vol). The eluate was 
dried in a vacuum centrifuge and   subjected to a radioimmu-
noassay for Ang II. The antiserum to Ang II (GE Healthcare, 
Buckinghamshire, UK) showed <1% cross-reactivity with Ang 
I, and 100% cross-reactivity with Ang III (heptapeptide), Ang II 
(3–8) (hexapeptide), and Ang II (4–8) (pentapeptide).
Statistical analysis. Values are reported as the mean ± s.e.m. 
Statistical analysis was done with Student’s t-test for unpaired 
data,  two-way  analysis  of  variance,  or  Duncan’s  multiple 
range test.
results
expression of c3 and the c3a receptor in VsMcs
To assess C3 and receptor systems, we evaluated expression 
of pre-pro-C3 mRNA, C3 protein and C3a receptor mRNA 
in  VSMCs  from  SHR  and  WKY  rats.  The  abundance  of 
  pre-pro-C3 mRNA was significantly (P < 0.01) higher in the 
VSMCs from SHR than in cells from WKY rats (Figure 1a). 
C3 protein was not expressed in cells from WKY rats, although 
it was increased with 10 ng/ml interferon-γ, whereas the abun-
dance of C3 protein was signicantly (P < 0.05) higher in VSMCs 
from SHR rats than WKY rats, and C3 was also increased 
  significantly (P < 0.05) with interferon-γ (Figure 1b). VSMCs 
from  SHR  and  WKY  rats  expressed  C3a  receptor  mRNA. 
There were no differences in the abundances of C3a receptors 
between either strain (Figure 1c).
effects of the c3a receptor inhibitor on proliferation of VsMcs
Figure 2 shows the effects of C3a receptor inhibitor, SB290157, 
on  proliferation  of  VSMCs  from  SHR  and  WKY  rats.  The 
increase in cell numbers in cultures grown in DMEM con-
taining 5% calf serum was higher in VSMCs from SHR than 
in  cells  from  WKY  rats.  SB290157  significantly  (P  <  0.05) 
inhibited the increase in the number of VSMCs in SHR rats, 
whereas SB290157 did not affect the increase in the number of 
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Figure 1 | Expression of complement 3 (c3) and the c3a receptor in vascular smooth muscle cells (VSmcs) from spontaneously hypertensive rats (Shr) and 
Wistar–Kyoto (WKY) rats. Total rNa was extracted from quiescent VSmcs of 3-week-old Shr and WKY rats. Semiquantitative determination of the abundance 
of (a) c3 and (c) c3a receptor messenger rNa (mrNa) was performed by reverse transcription and Pcr analysis. The ratio of each mrNa to 18S ribosomal 
rNa (rrNa) was evaluated by analysis of amplified Pcr products. Data were expressed as mean ± s.e.m. (n = 6 from two analyses). (b) Western blot analysis of 
expression of c3 protein in cultured VSmcs from Shr and WKY rats without or with interferon-γ (IFN-γ). Quiescent VSmcs from 3-week-old Shr and WKY rats 
were incubated without (control) or with 10 ng/ml IFN-γ for 20 h. The ratio of abundance of IFN-γ protein to α-tubulin was evaluated by densitometric analysis. 
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Figure 2 | Effects of the complement 3a receptor inhibitor, SB290157, on 
proliferation of vascular smooth muscle cells (VSmcs) from spontaneously 
hypertensive rats (Shr) and Wistar–Kyoto (WKY) rats. VSmcs were inoculated 
at 5 × 104 cells/cm2 in DmEm containing 5% calf serum without (control) or 
with 0.1 µmol/l SB290157. cells were replenished with DmEm containing 
5% calf serum and 0.1 µmol/l SB290157 every 24 h. They were trypsinized 
at 24, 48, and 72 h after inoculation, and cell number was determined in a 
coulter counter. Data are means ± s.e.m. (n = 8). *P < 0.01 vs. control. DmEm, 
Dulbecco’s modified Eagle’s medium.AMERICAN JOURNAL OF HYPERTENSION | VOLUmE 25 NUmBEr 3 | march 2012     287
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effects of the c3a receptor inhibitor on the  
phenotype of VsMcs
Basal  abundances  of  SM22α  mRNA  as  a  marker  for  the 
  contractile phenotype of VSMCs were significantly (P < 0.05) 
lower in VSMCs from SHR rats than in cells from WKY rats 
(Figure  3a).  Basal  abundances  of  osteopontin  mRNA  as  a 
marker for the synthetic phenotype of VSMCs were signifi-
cantly (P < 0.05) higher in VSMCs from SHR rats than in cells 
from WKY rats (Figure 3b). These findings indicate that the 
phenotype of VSMCs from SHR is more synthetic than in cells 
from WKY rats in serum deprivation. The C3a receptor inhibi-
tor SB290157 significantly (P < 0.05) increased the abundance 
of SM22α mRNA (Figure 3a) and decreased the abundance 
of osteopontin mRNA in VSMCs from SHR rats (Figure 3b), 
but  these  did  not  occur  in  cells  from  WKY  rats,  indicat-
ing that endogenous C3a induces the synthetic phenotype of 
  SHR-derived VSMCs.
effects of the c3a receptor inhibitor on expression  
of klF-5 mrna in VsMcs
Figure  4  shows  the  effects  of  the  SB290157  C3a  receptor 
inhibitor on expression of KLF-5 mRNA in VSMCs from SHR 
and WKY rats. Basal abundances of KLF-5 mRNA were sig-
nificantly higher (P < 0.05) in VSMCs from SHR than in cells 
from WKY rats. SB290157 significantly (P < 0.05) decreased 
the abundance of KLF-5 mRNA in VSMCs from SHR rats, but 
SB290157 did not affect the abundance of KLF-5 mRNA in 
cells from WKY rats.
effects of the c3a receptor inhibitor on ang ii-production  
in VsMcs
Figure 5 shows the effects of the SB290157 C3a receptor inhib-
itor on Ang II-production in VSMCs from SHR and WKY rats. 
Basal production of Ang II was significantly higher (P < 0.05) 
in VSMCs from SHR than in cells from WKY rats. Incubation 
with SB290157 significantly (P < 0.05) decreased production 
of Ang II in VSMCs from SHR, but it did not affect production 
of Ang II in cells from WKY rats.
discussion
In the present study, we confirmed that SHR-derived VSMCs 
abundantly express pre-pro-C3 mRNA and produce C3 pro-
tein when compared to cells from WKY rats. We previously 
evaluated the expression of 1,300 transcripts by microarray 
analysis  with  total  mRNA  extracted  from  the  mid-layer  of 
smooth aortic muscle from 3-week-old prehypertensive SHR 
and WKY rats in vivo. mRNAs encoding six genes including 
pre-pro-C3 were expressed only in aortic smooth muscle from 














































































Figure 3 | Effects of the complement 3a receptor inhibitor, SB290157, on expression of the mrNas of the phenotypic markers, (a) Sm22α and (b) osteopontin, 
in vascular smooth muscle cells (VSmcs) from spontaneously hypertensive rats (Shr) and Wistar–Kyoto (WKY) rats. Quiescent VSmcs from 3-week-old Shr and 
WKY rats were incubated without (control) or without 0.1 µmol/l SB290157 for 24 h. Total rNa was extracted and the abundance of Sm22α and osteopontin 
mrNas was evaluated by reverse transcription and Pcr analysis. The ratio of abundance of each mrNa to 18S rrNa was evaluated by densitometric analysis. 
































Figure 4 | Effects of the complement 3a receptor inhibitor, SB290157, on 
expression of Kruppel-like factor 5 (KLF-5) mrNas in vascular smooth muscle 
cells (VSmcs) from spontaneously hypertensive rats (Shr) and Wistar–Kyoto 
(WKY) rats. Quiescent VSmcs from 3-week-old Shr and WKY rats were 
incubated without (control) or without 0.1 µmol/l SB290157 for 24 h. Total 
rNa was extracted and the abundance of KLF-5 mrNas was evaluated by 
reverse transcription and Pcr analysis. The ratio of abundance of each mrNa 
to 18S rrNa was evaluated by densitometric analysis. Data are means ± s.e.m. 
(n = 8 from two analyses). *P < 0.05 between the indicated columns. mrNa, 
messenger rNa.288     march 2012 | VOLUmE 25 NUmBEr 3 | AMERICAN JOURNAL OF HYPERTENSION
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pre-pro-C3 mRNA was detected only in cultured VSMCs from 
SHR, not in cells from WKY rats in vitro.11 In the microarray 
analysis, there were no differences in the levels of mRNA for 
C4, C8, and C9 in aortic smooth muscle from SHR and WKY 
rats. These results indicated that the abundant expression of 
C3 in SHR-derived VSMCs is independent of the complement 
generating pathways.
Ueda et al.18 showed that C3 is produced by human aor-
tic VSMCs but not by a human smooth muscle cell line or 
VSMCs from human umbilical cord vein. Thus C3-production 
may differ between smooth muscle cell types. Thus since the 
enhanced  expression  of  pre-pro-C3  in  VSMCs  from  SHR 
might be associated with genetic alterations, we therefore per-
formed the direct sequencing of PCR products for promoter 
lesions of pre-pro-C3 in genomic DNA extracted from liver of 
SHR and WKY rats. However, there were no sequence differ-
ences in pre-pro-C3 promoter lesions between the two strains 
(data not shown). It is possible that the enhanced expression 
of pre-pro-C3 in VSMCs from SHR is associated with epige-
netic alterations. Further investigation is required to clarify the 
different expression of pre-pro-C3 in VSMCs from SHR and 
WYK rats.
In the present study, we examined effects of a C3a receptor 
inhibitor on proliferation, phenotype, and Ang II-production 
of VSMCs from SHR and WKY rats, to evaluate whether C3 
or C3a is associated with the exaggerated growth in the syn-
thetic  phenotype  and  Ang  II-production  in  SHR-derived 
VSMCs.  Expression  of  SM22α  mRNA  was  relatively  low, 
whereas  expression  of  osteopontin  mRNA  was  relatively 
high in quiescent VSMCs from SHR compared to cells from 
WKY  rats,  indicating  that  SHR-derived  VSMCs  are  rather 
synthetic. SB290157 increased the low expression of SM22α 
and decreased the high expression of osteopontin mRNAs in 
VSMCs from SHR. These findings indicate that endogenous 
C3a acts to induce the synthetic phenotype of SHR-derived 
VSMCs as a final effector.
C3 has roles in immune defenses but has also been reported 
to exert several other biological functions. C3 produced by 
endothelial  cells,  monocytes/macrophages,  and  fibroblasts 
induces atherosclerosis via activation of several cytokines.19 
C3 is synthesized by embryonic cells and participates in cell 
differentiation  and  proliferation.20  C3  enhances  growth  of 
cancer cells,21 contributes to contraction of VSMCs directly or 
indirectly through the activation of basophils,22 and   activates 
MAP  kinase  in  endothelial  cells.23  Schraufstatter  et  al.24 
recently  demonstrated  that  C3a  maintains  dedifferentiation 
of mesenchymal stem cells by the phosphorylation of ERK1/2. 
Thus the C3 and C3a system may induce the synthetic pheno-
type of VSMCs by its dedifferentiating effects on the mesen-
chymal cells.
Concerning mechanisms underlying the synthetic pheno-
type of VSMCs from SHR compared to cells from WKY rats, 
the expression of KLF-5 mRNA was higher in SHR-derived 
VSMCs, and was inhibited by the C3a receptor antagonist in the 
present experiments. These results indicate that the increased 
expression of the C3–C3a system induces KLF-5, which pro-
motes  the  synthetic  phenotype  of  SHR-derived  VSMCs. 
In the cardiovascular system, KLF-5 is expressed abundantly 
in embryonic VSMCs but is decreased in the adult vascula-
ture.25 KLF-5 expression is markedly upregulated in activated 
VSMCs and myofibroblasts during atherosclerosis.25,26 KLF-5 
is implicated in alterations in VSMCs during the change to the 
synthetic phenotype, which includes alterations in gene expres-
sion, at the site of vascular injury.27 We previously demon-
strated that exogenous C3a increased the expression of KLF-5 
mRNA and promoter activity via ERK signaling in VSMCs.13 
These findings and the present study suggest that endogenous 
C3a induces the synthetic phenotype of SHR VSMCs from the 
stimulation of KLF-5.
Production of Ang II was increased in VSMCs from SHR, 
which was suppressed with the C3a receptor antagonist, indi-
cating that increases in the endogenous C3–C3a system are 
associated with increased Ang II-production. We have previ-
ously demonstrated that the increased Ang II-production in 
SHR-derived VSMCs is associated with the Ang II-generating 
proteinases such as cathepsin D and angiotensin-converting 
enzyme.7 VSMCs that display the synthetic phenotype have 
a reduced fractional volume of myofilaments and many syn-
thetic organelles such as Golgi, mitochondria, and endoplas-
mic reticulum, which generate proteolytic enzymes including 
cathepsin D and angiotensin-converting enzyme, which pro-
duce Ang II, as well as growth factors and cytokines.28,29 It is 
possible  that  endogenous  C3a  contributes  to  the  increased 
Ang  II-production  through  the  induction  of  the  synthetic 
  phenotype of SHR-derived VSMCs.
Taken  together,  SHR-derived  VSMCs  primarily  produce 
C3–C3a,  but  this  does  not  occur  in  cells  from  WKY  rats. 
Endogenous C3a promotes transcriptional activation of KLF-5 
to induce the exaggerated growth with a synthetic phenotype 
and the production of Ang II in VSMCs from SHR.
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Figure 5 | Effects of the complement 3a receptor inhibitor, SB290157, on 
production of angiotensin II (ang II) in conditioned medium of vascular 
smooth muscle cells (VSmcs) from spontaneously hypertensive rats (Shr) 
and Wistar–Kyoto (WKY) rats. VSmcs (106) were incubated first for 24 h with 
serum-free DmEm and then for 48 h with 2 ml of fresh serum-free DmEm 
in the absence or presence of 0.1 µmol/l SB290157. The culture medium 
was collected and subjected to radioimmunoassay for ang II. Data are 
means ± s.e.m. (n = 6). *P < 0.05 between indicated columns. DmEm, 
Dulbecco’s modified Eagle’s medium.AMERICAN JOURNAL OF HYPERTENSION | VOLUmE 25 NUmBEr 3 | march 2012     289
original contributions Role of C3a in SHR VSMC
1.  Sen S, Tarazi RC, Khairallah PA, Bumpus FM. Cardiac hypertrophy in spontaneously 
hypertensive rats. Circ Res 1974; 35:775–781.
2.  Folkow B. Structure and function of the arteries in hypertension. Am Heart J 1987; 
114:938–948.
3.  Folkow B. The fourth Volhard lecture: cardiovascular structural adaptation; its role 
in the initiation and maintenance of primary hypertension. Clin Sci Mol Med Suppl 
1978; 4:3s–22s.
4.  Gray SD. Spontaneous hypertension in the neonatal rat. A review. Clin Exp 
Hypertens A 1984; 6:755–781.
5.  Walter SV, Hamet P. Enhanced DNA synthesis in heart and kidney of newborn 
spontaneously hypertensive rats. Hypertension 1986; 8:520–525.
6.  Hadrava V, Tremblay J, Hamet P. Abnormalities in growth characteristics of aortic 
smooth muscle cells in spontaneously hypertensive rats. Hypertension 1989; 
13:589–597.
7.  Hu WY, Fukuda N, Kanmatsuse K. Growth characteristics, angiotensin II generation, 
and microarray-determined gene expression in vascular smooth muscle cells from 
young spontaneously hypertensive rats. J Hypertens 2002; 20:1323–1333.
8.  Fukuda N, Satoh C, Hu WY, Soma M, Kubo A, Kishioka H, Watanabe Y, Izumi Y, 
Kanmatsuse K. Production of angiotensin II by homogeneous cultures of vascular 
smooth muscle cells from spontaneously hypertensive rats. Arterioscler Thromb 
Vasc Biol 1999; 19:1210–1217.
9.  Fukuda N, Hu WY, Satoh C, Nakayama M, Kishioka H, Kubo A, Kanmatsuse K. 
Contribution of synthetic phenotype on the enhanced angiotensin II-generating 
system in vascular smooth muscle cells from spontaneously hypertensive rats.  
J Hypertens 1999; 17:1099–1107.
10.  Hu WY, Fukuda N, Satoh C, Jian T, Kubo A, Nakayama M, Kishioka H, Kanmatsuse K. 
Phenotypic modulation by fibronectin enhances the angiotensin II-generating 
system in cultured vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 
2000; 20:1500–1505.
11.  Lin ZH, Fukuda N, Jin XQ, Yao EH, Ueno T, Endo M, Saito S, Matsumoto K, 
Mugishima H. Complement 3 is involved in the synthetic phenotype and 
exaggerated growth of vascular smooth muscle cells from spontaneously 
hypertensive rats. Hypertension 2004; 44:42–47.
12.  Wan JX, Fukuda N, Endo M, Tahira Y, Yao EH, Matsuda H, Ueno T, Matsumoto K. 
Complement 3 is involved in changing the phenotype of human glomerular 
mesangial cells. J Cell Physiol 2007; 213:495–501.
13.  Yao EH, Fukuda N, Ueno T, Tsunemi A, Endo M, Matsumoto K. Complement 3 
activates the KLF5 gene in rat vascular smooth muscle cells. Biochem Biophys Res 
Commun 2008; 367:468–473.
14.  de Bruijn MH, Fey GH. Human complement component C3: cDNA coding 
sequence and derived primary structure. Proc Natl Acad Sci USA 1985; 82:708–712.
15.  Sahu A, Lambris JD. Structure and biology of complement protein C3, a connecting 
link between innate and acquired immunity. Immunol Rev 2001; 180:35–48.
16.  Hu WY, Fukuda N, Ikeda Y, Suzuki R, Tahira Y, Takagi H, Matsumoto K, Kanmatsuse K, 
Mugishima H. Human-derived vascular smooth muscle cells produce angiotensin 
II by changing to the synthetic phenotype. J Cell Physiol 2003; 196:284–292.
17.  Mocharla H, Mocharla R, Hodes ME. Coupled reverse transcription-polymerase 
chain reaction (RT-PCR) as a sensitive and rapid method for isozyme genotyping. 
Gene 1990; 93:271–275.
18.  Ueda Y, Nagasawa K, Tsukamoto H, Horiuchi T, Nishizaka H, Ikeda K, Niho Y. 
Production of the third and fourth component of complement (C3, C4) by 
smooth muscle cells. Immunology 1996; 89:183–188.
19.  Buono C, Come CE, Witztum JL, Maguire GF, Connelly PW, Carroll M, Lichtman AH. 
Influence of C3 deficiency on atherosclerosis. Circulation 2002; 105:3025–3031.
20.  Hong MH, Jin CH, Sato T, Ishimi Y, Abe E, Suda T. Transcriptional regulation 
of the production of the third component of complement (C3) by 1 alpha, 
25-dihydroxyvitamin D3 in mouse marrow-derived stromal cells (ST2) and 
primary osteoblastic cells. Endocrinology 1991; 129:2774–2779.
21.  di Renzo L, Longo A, Morgante E, Mardente S, Prodinger WM, Russo M, Pontieri 
GM, Lipari M. C3 molecules internalize and enhance the growth of Lewis lung 
carcinoma cells. Immunobiology 1999; 200:92–105.
22.  Hugli TE, Müller-Eberhard HJ. Anaphylatoxins: C3a and C5a. Adv Immunol 1978; 
26:1–53.
23.  Monsinjon T, Gasque P, Chan P, Ischenko A, Brady JJ, Fontaine MC. Regulation 
by complement C3a and C5a anaphylatoxins of cytokine production in human 
umbilical vein endothelial cells. FASEB J 2003; 17:1003–1014.
24.  Schraufstatter IU, Discipio RG, Zhao M, Khaldoyanidi SK. C3a and C5a are 
chemotactic factors for human mesenchymal stem cells, which cause prolonged 
ERK1/2 phosphorylation. J Immunol 2009; 182:3827–3836.
25.  Nagai R, Suzuki T, Aizawa K, Shindo T, Manabe I. Significance of the transcription 
factor KLF5 in cardiovascular remodeling. J Thromb Haemost 2005; 3:1569–1576.
26.  Shiojima I, Aikawa M, Suzuki J, Yazaki Y, Nagai R. Embryonic smooth muscle 
myosin heavy chain SMemb is expressed in pressure-overloaded cardiac 
fibroblasts. Jpn Heart J 1999; 40:803–818.
27.  Watanabe N, Kurabayashi M, Shimomura Y, Kawai-Kowase K, Hoshino Y, Manabe I, 
Watanabe M, Aikawa M, Kuro-o M, Suzuki T, Yazaki Y, Nagai R. BTEB2, a Krüppel-
like transcription factor, regulates expression of the SMemb/Nonmuscle myosin 
heavy chain B (SMemb/NMHC-B) gene. Circ Res 1999; 85:182–191.
28.  Mosse PR, Campbell GR, Wang ZL, Campbell JH. Smooth muscle phenotypic 
expression in human carotid arteries. I. Comparison of cells from diffuse 
intimal thickenings adjacent to atheromatous plaques with those of the media. 
Lab Invest 1985; 53:556–562.
29.  Glukhova MA, Frid MG, Koteliansky VE. Developmental changes in expression of 
contractile and cytoskeletal proteins in human aortic smooth muscle. J Biol Chem 
1990; 265:13042–13046.